BGM
PRAX icon

Burkehill Global Management’s Praxis Precision Medicines PRAX Stock Holding History

Burkehill Global Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Hold
35,000
– – 0.42% 40
2026
Q1 		$11.3M Buy
35,000
+10,000
+40% +$3.09M 0.56% 43
2025
Q4 		$7.37M Buy
+25,000
New +$4.66M 0.49% 60

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Burkehill Global Management's PRAX Position: Q2 2026 in Review

Burkehill Global Management held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 35,000 shares worth $11.7M. The position accounts for 0.42% of the portfolio, ranked #40.

Burkehill Global Management first reported a position in PRAX in Q4 2025 and has held it in 3 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Burkehill Global Management held 35,000 shares of Praxis Precision Medicines worth $11.7M as of Q2 2026.
  • Burkehill Global Management left its Praxis Precision Medicines share count unchanged in Q2 2026.
  • Praxis Precision Medicines made up 0.42% of Burkehill Global Management's portfolio in Q2 2026, its #40 holding.
  • Burkehill Global Management first reported a position in Praxis Precision Medicines in Q4 2025 and has held it in 3 quarters since.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Burkehill Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.